Teva Pharmaceutical Industries Limited (NYSE:TEVA) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) have been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are currently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $13.78.

A number of research firms have issued reports on TEVA. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price objective on the stock in a research report on Friday, March 8th. Barclays upped their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the company an “overweight” rating in a research report on Monday, February 5th. StockNews.com upgraded Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. The Goldman Sachs Group upped their target price on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a “neutral” rating in a report on Monday, February 5th. Finally, Piper Sandler raised shares of Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $12.00 to $19.00 in a research report on Monday, February 12th.

Insider Transactions at Teva Pharmaceutical Industries

In other Teva Pharmaceutical Industries news, EVP Mark Sabag sold 100,000 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the sale, the executive vice president now owns 382,590 shares in the company, valued at $5,172,616.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other news, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 5th. The stock was sold at an average price of $13.52, for a total value of $1,352,000.00. Following the sale, the executive vice president now directly owns 382,590 shares of the company’s stock, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Eric Drape sold 173,261 shares of the firm’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $13.05, for a total value of $2,261,056.05. Following the transaction, the vice president now directly owns 1 shares of the company’s stock, valued at approximately $13.05. The disclosure for this sale can be found here. Insiders have sold 358,972 shares of company stock valued at $4,739,820 in the last three months. 0.55% of the stock is currently owned by company insiders.

Institutional Trading of Teva Pharmaceutical Industries

Several institutional investors have recently bought and sold shares of the company. Harel Insurance Investments & Financial Services Ltd. lifted its stake in shares of Teva Pharmaceutical Industries by 184,642.3% in the third quarter. Harel Insurance Investments & Financial Services Ltd. now owns 27,711,340 shares of the company’s stock worth $282,656,000 after buying an additional 27,696,340 shares in the last quarter. Sound Shore Management Inc CT bought a new position in Teva Pharmaceutical Industries in the 3rd quarter valued at approximately $80,791,000. FMR LLC increased its holdings in shares of Teva Pharmaceutical Industries by 3,553.8% in the 3rd quarter. FMR LLC now owns 2,564,339 shares of the company’s stock worth $26,156,000 after purchasing an additional 2,494,156 shares in the last quarter. Clal Insurance Enterprises Holdings Ltd raised its stake in shares of Teva Pharmaceutical Industries by 7.1% in the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 32,804,131 shares of the company’s stock worth $342,788,000 after purchasing an additional 2,188,212 shares during the last quarter. Finally, Meitav Investment House Ltd. lifted its holdings in shares of Teva Pharmaceutical Industries by 82.8% during the fourth quarter. Meitav Investment House Ltd. now owns 4,305,674 shares of the company’s stock valued at $44,914,000 after purchasing an additional 1,950,500 shares in the last quarter. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Stock Down 0.7 %

Shares of NYSE TEVA opened at $13.96 on Wednesday. The company has a market cap of $15.65 billion, a price-to-earnings ratio of -29.70, a PEG ratio of 1.67 and a beta of 1.04. The company has a quick ratio of 0.69, a current ratio of 1.02 and a debt-to-equity ratio of 2.23. The firm’s fifty day moving average is $13.64 and its 200 day moving average is $11.69. Teva Pharmaceutical Industries has a 52 week low of $7.09 and a 52 week high of $14.47.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.